Biblio Discovery — Demo Discovery Service

9 results for "Mark Boguniewicz"

Showing 1–9 · 0.34 seconds · RSS

  1. Journal Article

    Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life

    Andrew Blauvelt; Mark Boguniewicz; Patrick M. Brunner et al.

    Journal of Dermatological Treatment, Vol. 33 No. 5 · 2022 · English · DOAJ Scopus

    Background Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials.Methods These analyses included data for Investigator’s Global Assessment responder (clear [0] or almost…

  2. Journal Article

    Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families

    Eric L. Simpson; Amy S. Paller; Mark Boguniewicz et al.

    Dermatology and Therapy, Vol. 8 No. 4 · 2018 · English · DOAJ Scopus

    Abstract Introduction The impact of crisaborole ointment, a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis (AD), on quality of life (QoL) was assessed in two identically designed phase 3 studies (AD-301: NCT02118766; AD-302: NCT02118792, both at…

  3. Journal Article

    Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long‐term efficacy and patient‐reported outcomes

    Eric Simpson; April Armstrong; Mark Boguniewicz et al.

    Dermatologic Therapy, Vol. 35 No. 12 · 2022 · English · DOAJ Scopus

    Abstract To address the need for long‐term efficacy and patient‐reported outcomes (PROs) data for patients with atopic dermatitis (AD) treated with baricitinib 2 mg, a study was conducted to evaluate the efficacy of baricitinib 2 mg in adult patients with moderate‐to‐severe AD. Data presented here…

  4. Journal Article

    Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis

    Jonathan I. Silverberg; Eric L. Simpson; Mark Boguniewicz et al.

    Acta Dermato-Venereologica, Vol. 101 No. 11 · 2021 · English · DOAJ Scopus

    Optimal management of atopic dermatitis requires a comprehensive assessment of response to treatment in order to inform therapeutic decisions. In a real-world setting, successful response to atopic dermatitis treatment is measured by sustained improvements in signs, symptoms, and quality of life…

  5. Journal Article

    Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus

    Mark Boguniewicz, MD; Moise L. Levy, MD; Lawrence F. Eichenfield, MD et al.

    Journal of Pediatrics: Clinical Practice, Vol. 14 · 2024 · English · DOAJ Scopus

    Objective: This expert-led consensus aims to provide primary care providers (PCPs) with recommendations for the care of atopic dermatitis (AD) in patients aged

  6. Journal Article

    Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis

    Eric L. Simpson; Jonathan I. Silverberg; Vimal H. Prajapati et al.

    Dermatology and Therapy, Vol. 15 No. 8 · 2025 · English · DOAJ Scopus

    Abstract Introduction Achievement of stringent outcomes (e.g., ≥ 90% improvement from baseline in Eczema Area and Severity Index [EASI 90] or minimal-to-no itch on the Worst Pruritus Numerical Rating Scale [WP-NRS 0/1]) is associated with a substantial improvement in quality of life among patients…

  7. Journal Article Full text

    Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

    Amy S. Paller; Elaine C. Siegfried; Diamant Thaçi et al.

    Journal of the American Academy of Dermatology · 2020 · English · OpenAlex Scopus

    BACKGROUND: Children with severe atopic dermatitis (AD) have limited treatment options. OBJECTIVE: We report the efficacy and safety of dupilumab + topical corticosteroids (TCS) in children aged 6-11 years with severe AD inadequately controlled with topical therapies. METHODS: In this double-blind…